Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmuPharma ( (GB:IMM) ) has provided an update.
ImmuPharma will host a live investor presentation on the Investor Meet Company platform on 20 March 2026, led by CEO Tim McCarthy, CSO Dr Sébastien Goudreau and COO Dr Tim Franklin. The session will discuss its recent update on the P140 programme, accelerated development of Kapiglucagon for Type 1 diabetes and a funding initiative to raise up to £7.5 million.
The online event is open to existing and potential shareholders, with questions accepted in advance and during the webcast, and a replay to be posted on ImmuPharma’s website. By using the interactive platform, the company is seeking to deepen investor engagement around its R&D pipeline and financing plans, which could be pivotal for advancing its clinical programmes and shaping market perception.
The most recent analyst rating on (GB:IMM) stock is a Sell with a £6.00 price target. To see the full list of analyst forecasts on ImmuPharma stock, see the GB:IMM Stock Forecast page.
Spark’s Take on IMM Stock
According to Spark, TipRanks’ AI Analyst, IMM is a Neutral.
The score is weighed down primarily by very weak financial performance (near-zero revenue, persistent losses, ongoing cash burn, and negative equity). Technicals are mixed but modestly supportive versus the 200-day average, while valuation remains challenged due to losses and the absence of dividend yield.
To see Spark’s full report on IMM stock, click here.
More about ImmuPharma
ImmuPharma PLC is a specialty biopharmaceutical company focused on discovering and developing peptide-based therapeutics. Its portfolio includes novel peptide drugs targeting autoimmune diseases and anti-infective indications, positioning the group within niche, innovation-led segments of the life sciences market.
Average Trading Volume: 3,491,688
Technical Sentiment Signal: Buy
Current Market Cap: £27.2M
For a thorough assessment of IMM stock, go to TipRanks’ Stock Analysis page.